Quanterix Announces Second Bi-annual Conference, “Proteins Powering Nexgen Healthcare: San Francisco”
Lexington, MA – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that it is hosting its second bi-annual conference, entitled, “Proteins Powering NexGen Healthcare: San Francisco,” on October 29, 2015, from 9:00 a.m. – 5:00 p.m. PT at the Embassy Suites South San Francisco Airport in South San Francisco, CA.
The conference will focus on the incredible potential of biomarkers to impact personalized medicine and healthcare, thanks to high-fidelity detection technologies such as the company’s Simoa HD-1 Analyzer platform. It will present a tremendous opportunity to learn about the growing importance of protein biomarkers from researchers at leading institutions and companies. Some of the world’s leading researchers in their fields will share presentations showcasing the application of those new tools to a wide range of therapeutic areas, including inflammation, neurology, cardiology, infectious disease and more.
“This conference is positioned to be the most compelling yet. With game-changing data being presented on ultra-low concentration blood biomarkers in all disease types, these discussions will further reinforce the incredible promise of this rapidly evolving field,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “After heavily re-engineering our Simoa technology, we are also excited to introduce our next-generation platform publicly for the first time, showcasing its game-changing capabilities for disease detection much earlier and more accurately in its progression.”
Joined by fellow researchers and thought leaders who are blazing uncharted territory in their pursuit of in-vitro diagnostics and laboratory developed tests for important links to advance the treatment of disease, Hrusovsky will kick off the conference by discussing how to inspire a revolution in personalized healthcare through exploiting the power of the protein. Prominent researchers, such as Dr. Robert Stern, Professor of Neurology, Neurosurgery and Anatomy and Neurobiology at Boston University School of Medicine, and Dr. Jessica Gill, tenure track investigator and Lasker Clinical Research Scholar at the National Institute of Health, will share insight on novel research highlighting the promise of neurological biomarkers in the detection and quantification of traumatic brain injury. The full list of presentations includes:
- “Inspiring a Revolution in Personalized Healthcare by Exploiting the Power of the Protein,” Kevin Hrusovsky, CEO and Executive Chairman, Quanterix
- “Mechanistic-based Biomarkers for Cardiovascular Disease,” Dr. Jenny Van Eyk, Director Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center
- “Searching for Elusive Serum Cytokine Biomarkers in Asthma,” Dr. Monica Gavala, Senior Associate Scientist in the Inflammation Therapeutic Area (TA), Amgen
- “Chronic Traumatic Encephalopathy: Potential Biomarkers and Clinical Presentation,” Dr. Robert Stern, Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology at Boston University School of Medicine, where he is also Director of the Clinical Core of the BU Alzheimer’s Disease Center and Director of Clinical Research for the BU Chronic Traumatic Encephalopathy (CTE) Center
- “Overview of Simoa Ultra-Sensitive Technology and Selected Case Studies,” Dr. David Duffy, Vice President, Research and Chief Technology Officer, Quanterix
- “A Cytokine Assay Challenge: Sensitivity and Specificity,” Jane Ruppel, Principal Scientific Researcher, Assay Development and Technology Department, Genentech
- “Development, Validation and Application of Ultrasensitive Simoa-based Immunoassays for Prospective Clinical Trials,” Dr. Dominic Eisinger, Vice President of Sales and Marketing, Myriad RBM
- “The Role of Tau and Amyloid in Acute and Chronic Symptoms Following TBI,” Kevin Hrusovsky, CEO and Executive Chairman, Quanterix
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit www.quanterix.com.
Nikki Festa & Caitlyn Keating
Share this page